NasdaqGS - Nasdaq Real Time Price USD

Kamada Ltd. (KMDA)

6.88

-0.06

(-0.86%)

At close: June 13 at 4:00:01 PM EDT

7.00

+0.12

+(1.74%)

After hours: June 13 at 4:24:50 PM EDT

Implied Volatility Surging for Kamada Stock Options

Investors need to pay close attention to Kamada stock based on the movements in the options market lately.

Zacks 4 days ago

KMDA.TA
Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet

The consensus price target hints at a 106.9% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 12 days ago

KMDA.TA
Are Investors Undervaluing Kamada (KMDA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 12 days ago

KMDA.TA
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

KMDA vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 17 days ago

CSLLY

KMDA.TA
Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

The mean of analysts' price targets for Kamada (KMDA) points to a 106.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 29 days ago

KMDA.TA
Is Kamada (KMDA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 29 days ago

KMDA.TA
Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion

Kamada Ltd (KMDA) reports a robust 17% revenue increase and advances its growth strategy despite challenges in Cytogam sales and rising tax rates.

GuruFocus.com last month

KMDA.TA
Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks last month

KMDA.TA
Kamada (KMDA) Q1 Earnings Match Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 0% and 5.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

KMDA.TA
Kamada: Q1 Earnings Snapshot

REHOVOT, Israel (AP) — Kamada Ltd. (KMDA) on Wednesday reported first-quarter net income of $4 million. On a per-share basis, the Rehovot, Israel-based company said it had profit of 7 cents. The results met Wall Street expectations.

Associated Press Finance last month

KMDA.TA
Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growt

GlobeNewswire last month

KMDA
-0.86%
Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Besides Wall Street's top -and-bottom-line estimates for Kamada (KMDA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Zacks last month

KMDA.TA
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 400% and 4.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

KMDA.TA
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0% and 23.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

NUVB

KMDA.TA
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

Company to Host Conference Call at 8:30am ETREHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wedne

GlobeNewswire last month

KMDA
-0.86%
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWI

GlobeNewswire last month

KMDA
-0.86%
Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company’s ordinary s

GlobeNewswire 2 months ago

KMDA
-0.86%
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-DSpecialty Plasma Collected will Support the Company’s Increasing Demand for Hyper-Immune Plasma, and is Expected to Lower Raw Material CostsExpected Annual Revenue Contribution from Sales of Normal Source Plasma is Estimated at $8 Million to $10 Million at Full CapacityNew Center Opening Furt

GlobeNewswire 2 months ago

KMDA
-0.86%
Sidoti Events, LLC's Virtual March Small-Cap Conference

NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March ...

ACCESS Newswire 2 months ago

KMDA
-0.86%

MTUS

LCUT
Kamada Ltd (KMDA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives

Kamada Ltd (KMDA) reports a 13% revenue increase and unveils plans for biosimilar launches and plasma center expansions.

GuruFocus.com 3 months ago

KMDA.TA

Performance Overview

Return	KMDA	^TA125.TA (^TA125.TA)
YTD	+18.15%	+12.20%
1-Year	+39.04%	+38.49%
3-Year	+59.75%	+45.64%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kamada Ltd. (KMDA)

Implied Volatility Surging for Kamada Stock Options

Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet

Are Investors Undervaluing Kamada (KMDA) Right Now?

KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

Is Kamada (KMDA) Stock Undervalued Right Now?

Kamada Ltd (KMDA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion

Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics

Kamada (KMDA) Q1 Earnings Match Estimates

Kamada: Q1 Earnings Snapshot

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

Sidoti Events, LLC's Virtual March Small-Cap Conference

Kamada Ltd (KMDA) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives

Performance Overview